Key indicators: single-crystal X-ray study; T = 298 K; mean (C-C) = 0.003 Å; disorder in main residue; R factor = 0.061; wR factor = 0.164; data-to-parameter ratio = 9.9.
Related literature
For the biological activity of quinazoline-4(3H)-one derivatives, see: Pandeya et al.(1999) ; Shiba et al. (1997) , Malamas & Millen (1991) ; Mannschreck et al. (1984) ; Kung et al. (1999) ; Bartroli et al. (1998) ; Palmer et al. (1997) ; Tsou et al. (2001) ; Matsuno et al. (2002) . For the synthesis of the title compound, see: Yang et al. (2008) .
Experimental
Crystal data C 17 H 15 F 3 N 4 O 2 M r = 364.33 Orthorhombic, Pbcn a = 11.9675 (13) Å b = 12.9579 (13) Å c = 21.280 (2) Å V = 3300.0 (6) Å 3 Z = 8 Mo K radiation = 0.12 mm À1 T = 298 K 0.23 Â 0.15 Â 0.11 mm
Data collection
Bruker SMART APEX CCD areadetector diffractometer Absorption correction: multi-scan (SADABS; Sheldrick, 2001) T min = 0.973, T max = 0.987 15599 measured reflections 3076 independent reflections 2573 reflections with I > 2(I) R int = 0.083 Refinement R[F 2 > 2(F 2 )] = 0.061 wR(F 2 ) = 0.164 S = 1.12 3076 reflections 311 parameters 19 restraints H atoms treated by a mixture of independent and constrained refinement Á max = 0.39 e Å À3 Á min = À0.29 e Å À3 Table 1 Hydrogen-bond geometry (Å , ).
Cg1 is the centroid of the N1/C7/C1/C2/N2/C8 ring. Symmetry codes: (i) Àx þ 2; Ày þ 2; Àz þ 1; (ii) Àx þ 3 2 ; y À 1 2 ; z.
Data collection: SMART (Bruker, 2000); cell refinement: SAINT (Bruker, 2000); data reduction: SAINT; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008) ; program(s) used to refine structure: SHELXL97 (Sheldrick, 2008) ; molecular graphics: SHELXTL (Sheldrick, 2008) ; software used to prepare material for publication: SHELXTL. Quinazoline-4(3H)-one derivatives have numerous biological properties. Some of these activities include antimicrobial (Pandeya et al., 1999 and Shiba et al., 1997 ), antidiabetic (Malamas & Millen, 1991 ), anticonvulsant (Mannschreck et al., 1984 ), antibacterial (Kung et al., 1999 ), antifungal (Bartroli et al., 1998 , protein tyrosine kinase inhibitors (Palmer et al., 1997) , EGFR inhibitors (Tsou et al.,2001) and PDGFR phosphorylation inhibitors (Matsuno et al., 2002) . We have recently focused on the synthesis of heterocyclic compounds using an aza-Wittig reaction. We have reported the synthesis of the title compound (Yang et al., 2008) . We present here the crystal structure of the title compound, (I) ( Fig. 1) , which can be used as a precursor for obtaining bioactive molecules.
In the crystal structure, the fused benzene ring and the pyrimidinone ring are not completely co-planar, but are inclined at 0.67 (1) °. Significant and intermolecular N-H···O and N-H···N hydrogen bonds contribute strongly to the stability of the structure (Fig. 2 ). An intramolecular C-H···F hydrogen bond is also found. (Table 1 ). The crystal structure (Fig. 2) is also stabilized by weak intermolecular C-H···π hydrogen bonds (Table 1 ) and π-π stacking interactions with centroid-centroid separations of 3.673 (6), 3.779 (8), 3.674 (6) and 3.780 (8) Å for Cg1···Cg3 i , Cg1···Cg4 i , Cg3···Cg1 ii and Cg4···Cg1 ii , respectively, where Cg1, Cg3 and Cg4 are the centroids of the N1/C7/C1-C2/N2/C8, C11-C16 and C11-C13/C14'-C16' rings, respectively [symmetry code: (i) 3/2-X, 1/2+Y, Z, (ii) 3/2-X, -1/2+Y, Z,].
Experimental
The title compound was prepared by a literature method (Yang et al., 2008) . Single crystals suitable for X-ray diffraction were obtained from a methanol-dichloromethane (1:1 v/v) solution at room temperature.
Refinement
H atoms bonded to C were placed in calculated positions, with C-H distances of 0.97 and 0.93Å for H atoms bonded to sp 3 and sp 2 C atoms, respectively. They were refined using a riding model, with U iso (H) = 1.2U eq (C), or 1.5U eq (methyl C). The H atoms bound to N were refined with distance restraints N-H = 0.86 (2)Å and with U iso (H) = 1.2U eq (N). The C14···C16 atoms of the trifluoromethoxy-substituted benzene ring and all atoms of the trifluoromethoxy substituent were disordered over two sites. The site occupancies refined to 0.51 and 0.49 and were fixed at these values in the final refinement cycles. Fig. 1 . View of the molecular structure of (I), showing the atom labelling schemeand with displacement ellipsoids drawn at the 50% probability level. Both disorder components are shown with bonds involving the minor disorder component drawn as dashed lines. (3) C15'-C16' 1.37 (4) C9-C10 1.517 (4) C15'-H15' 0.9300 C9-H9A 0.9700 C16'-H16' 0.9300 C9-H9B 0.9700 C17'-F2' 1.299 (9) C10-N3 1.464 (4) C17'-F3' 1.320 (9) C10-H10A 0.9700 C17'-F1' 1.325 (9) C10-H10B 0.9700 C17'-O2' 1.325 (9) C11-C16 1.379 (18) N3-H3A 0.862 (11) C11-C12 1.381 (3) N3-H3B 0.864 (11) C11-C16' 1.38 (3) N4-H4A 0.863 (11) C2-C1-C6 119.7 (2) C14-C13-C12 119.9 (5) C2-C1-C7 119.4 (2) C14'-C13-H13 121.6 C6-C1-C7 120.9 (2) C14-C13-H13 120.1
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Hydrogen-bond geometry (Å, °)
Cg1 is the centroid of the N1/C7/C1/C2/N2/C8 ring. 
